{
"id":"mk19_b_rm_q075",
"number":75,
"bookId":"rm",
"correctAnswer":"B",
"title":"Question 75",
"stimulus":[
{
"type":"p",
"hlId":"503b47",
"children":[
"A 19-year-old woman is evaluated for recent onset of a malar rash and arthralgia, which limits her daily activities."
]
},
{
"type":"p",
"hlId":"32a94a",
"children":[
"On physical examination, vital signs are normal. She has an edematous, erythematous malar rash and small joint tenderness and swelling in several proximal interphalangeal joints, metacarpophalangeal joints, wrists, and ankles. The remainder of the physical examination is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"82aa14",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Erythrocyte sedimentation rate",
"children":[
"Erythrocyte sedimentation rate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"6e1cec",
"class":"cell text l",
"children":[
"35 mm/h"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"fcac73",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Platelet count",
"children":[
"Platelet count"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"2424a9",
"class":"cell text l",
"children":[
"92,000/μL (92 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"0ab714",
"class":"cell text l",
"children":[
"Comprehensive metabolic panel"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"960b44",
"class":"cell text l",
"children":[
"Normal"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"61f3aa",
"class":"cell text l",
"children":[
"C3 complement"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"960b44",
"class":"cell text l",
"children":[
"Normal"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"323d2d",
"class":"cell text l",
"children":[
"C4 complement"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"960b44",
"class":"cell text l",
"children":[
"Normal"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"131f5a",
"class":"cell text l",
"children":[
"Anti–double-stranded DNA antibodies"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"328929",
"class":"cell text l",
"children":[
"Positive"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"b534b1",
"class":"cell text l",
"children":[
"Antinuclear antibodies"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"027c43",
"class":"cell text l",
"children":[
"1:1280 homogenous"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"960b44",
"class":"cell text l",
"children":[
"Normal"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"9965af",
"children":[
"Chest radiograph is normal."
]
},
{
"type":"p",
"hlId":"eb7a8d",
"children":[
"Sun protection, including use of a broad-spectrum sunscreen, is recommended."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"78ff87",
"children":[
"Which of the following is the most appropriate additional treatment?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Prednisone"
}
},
{
"letter":"B",
"text":{
"__html":"Prednisone and hydroxychloroquine"
}
},
{
"letter":"C",
"text":{
"__html":"Prednisone, hydroxychloroquine, and cyclophosphamide"
}
},
{
"letter":"D",
"text":{
"__html":"Topical hydrocortisone cream"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"cac470",
"children":[
"First-line therapy for most patients with systemic lupus erythematosus includes hydroxychloroquine with glucocorticoids."
]
},
{
"type":"keypoint",
"hlId":"c523a9",
"children":[
"Hydroxychloroquine is a mainstay of treatment in systemic lupus erythematosus because it reduces disease-associated damage, prevents disease flares, and improves kidney and overall survival."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"0fe66a",
"children":[
"The most appropriate treatment is prednisone and hydroxychloroquine (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"). This patient has clear findings of new but relatively mild systemic lupus erythematosus (SLE). She has skin and joint involvement and thrombocytopenia without evidence of other organ involvement. First-line therapy for mild SLE includes hydroxychloroquine, often with glucocorticoids if a more rapid response is needed. Many patients will need additional immunomodulatory therapy at some point in their disease. Hydroxychloroquine is a mainstay of treatment in SLE because it reduces disease-associated damage, prevents disease flares, and improves kidney and overall survival. In addition, hydroxychloroquine may reduce the risk for thrombosis, liver disease, and myocardial infarction and improve lipid profiles. Glucocorticoids are also used in most patients with SLE, particularly in acute disease. After disease stabilizes, glucocorticoids are tapered to the lowest effective dosage, preferably to no more than 7.5 mg/d within 4 to 6 months, and should be discontinued entirely if possible. Glucocorticoid exposure, especially at high doses, should be limited because of associated risk for organ damage, infection, and premature mortality. Azathioprine or methotrexate is recommended if patients with mild disease have refractory symptoms. All patients with SLE should be counseled on sun protection, vaccinations, and lifestyle modifications to optimize cardiovascular health."
]
},
{
"type":"p",
"hlId":"4ecaac",
"children":[
"Prednisone alone (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") is likely to help with her current symptoms but is unlikely to provide lasting benefits after it is tapered or discontinued."
]
},
{
"type":"p",
"hlId":"6563ce",
"children":[
"For patients with more severe SLE manifestations, including nephritis, central nervous system disease, or other more severe manifestations, additional therapy is warranted. Induction with mycophenolate or cyclophosphamide (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") would be reasonable, in addition to glucocorticoids and hydroxychloroquine, in that setting. This patient does not require this degree of pharmacotherapy unless her disease progresses."
]
},
{
"type":"p",
"hlId":"2ee630",
"children":[
"All patients with a new diagnosis of SLE probably require some immunomodulatory therapy, such as hydroxychloroquine. Those with cutaneous symptoms alone can also be treated with topical agents, such as hydrocortisone cream (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"), and monitored carefully, but this patient has joint inflammation and hematologic findings that warrant intervention with additional systemic therapy."
]
}
],
"relatedSection":"mk19_b_rm_s7_4",
"objective":{
"__html":"Treat mild systemic lupus erythematosus."
},
"references":[
[
"Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78:736-745. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30926722",
"target":"_blank"
},
"children":[
"PMID: 30926722"
]
}
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":8,
"B":82,
"C":8,
"D":2,
"E":0
},
"hlIds":[
"503b47",
"32a94a",
"a462a3",
"82aa14",
"6e1cec",
"fcac73",
"2424a9",
"0ab714",
"960b44",
"61f3aa",
"960b44",
"323d2d",
"960b44",
"131f5a",
"328929",
"b534b1",
"027c43",
"747c2a",
"960b44",
"9965af",
"eb7a8d",
"78ff87",
"cac470",
"c523a9",
"0fe66a",
"4ecaac",
"6563ce",
"2ee630"
]
}